Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.

Authors:
Li J; Wang Q; Han Y; Jiang L; Lu S and 5 more

Journal:
J Hematol Oncol

Publication Year: 2023

DOI:
10.1186/s13045-023-01460-2

PMCID:
PMC10290401

PMID:
37353849

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Hematol Oncol

Abbreviation: J Hematol Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.
Zhao Z; Qin J; Qian Y and 11 more (2024) - Transparency Score: 3/6
Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future impl…
Zhao B; Wu B; Feng N and 4 more (2023) - Transparency Score: 3/6
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promisin…
Yang L; Chu Z; Liu M and 7 more (2023) - Transparency Score: 3/6
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and …
Short NJ; Muftuoglu M; Ong F and 24 more (2023) - Transparency Score: 4/6
A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic ef…
Li Y; Liu J; Chen W and 13 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding This work was supported by grants from the National Key Research and Development Program of China (2022YFA1103500), the National Natural Science Foundation of China (82222003, 92268117, 82161138028 and 31971318), the Zhejiang Provincial Natural Science Foundation of China Exploration Project (LQ21H180006), the Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2020R01006) and the China Postdoctoral Science Foundation (CPSF) (2021M702853)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025